Barclays Lowers MacroGenics (NASDAQ:MGNX) Price Target to $8.00
MacroGenics (NASDAQ:MGNX – Get Rating) had its price target reduced by Barclays from $18.00 to $8.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has an 'overweight' rating on the biopharmaceutical company's stock. Barclays‘s price target indicates a potential upside of 60.64% from the company's current price.
MGNX has been the subject of a number of other reports. JMP Securities reduced their price target on shares of MacroGenics from $24.00 to $20.00 and set a 'market outperform' rating for the company in a research note on Tuesday, July 12th.
Article
‘It's been...
ShowBiz Mi...
It is a sp...
Hiblocks (...
2023 Elect...
Albany Her...
Lorem ipsum dolor sit amet.
Praesent placerat ipsum nec mi maximus, vel cursus mauris cursus. Vivamus cursus ante eget orci egestas malesuada.
Article
Invesco Va...
Burleson &...
‘It's been...
ShowBiz Mi...
It is a sp...
Hiblocks (...